Adverse Effects of Newer Cephalosporins: An Update

Drug Safety

Volumn 9, Issue 2, 1993, Pages 132-142

  Thompson, Joseph W ^a   Jacobs, Richard F ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFACLOR; CEFALEXIN; CEFALORIDINE; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFIXIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; LATAMOXEF;

AGED; ANAPHYLAXIS; BRONCHOSPASM; CHOLELITHIASIS; CROSS ALLERGY; DIARRHEA; DRUG ERUPTION; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOPROTHROMBINEMIA; INFANT; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEWBORN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PEDIATRICS; PENICILLIN ALLERGY; PRESCHOOL CHILD; PSEUDOMEMBRANOUS COLITIS; REVIEW; SEIZURE; SERUM SICKNESS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUPERINFECTION; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VERTIGO; VOMITING;

CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HEART DISEASES; HEMATOLOGIC DISEASES; HUMAN; INFANT; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; NERVOUS SYSTEM DISEASES; SUPERINFECTION;

EID: 0027272288     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199309020-00005     Document Type: Review

References (51)

1. Phase I study of multiple-dose cefprozil and comparison with cefaclor
2. Drug allergenic determinants
3. Hypopro-thrombinemia associated with cefamandole use in a rural teaching hospital
4. Ceftriaxone binding to human serum albumin: competition with bilirubin
5. Comparative efficacy and safety of cefprozil (Brit-28100) and cefaclor in the treatment of acute Group A-haemolytic streptococcal pharyngitis
6. Multicenter clinical trial of cefoperazone sodium in the United States
7. A comparison of the effects of mezlocillin and carbenicillin on hemostasis in volunteers
8. Ceftriaxone therapy of serious bacterial infection
9. Safety of parenteral third-generation cephalosporins
10. Nosocomial pneumonia: comparative multi-center trial between monotherapy with cefotaxime and treatment with antibiotic combinations
11. A fatal case of ceftriaxone (Rocephin)-induced haemolytic anemia associated with intravascular immune haemolysis
12. The influence of third-generation cephalosporins on the aerobic intestinal flora
13. Ceftriaxone therapy in paediatric patients
14. Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population
15. Apparent biliary pseudolithiasis during ceftriaxone therapy
16. Cefaclor safety profile: a ten year review
17. A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients
18. Ceftriaxone-associated cholecystitis
19. Safety profile and efficacy of cefotaxime for the treatment of hospitalized children
20. Gram-positive superinfections following β-lactam chemotherapy: the significance of enterococcus
21. Comparative, multicenter studies of cefixime and amoxacillin in the treatment of respiratory tract infections
22. Gallbladder sludge and antibiotics
23. Quantitative comparison of adverse reactions to cefaclor vs
24. Production of hypoprothrombinemia by moxalactam and 1-methyl-5-thiotetrazole in rats
25. Comparative toxicities of third-generation cephalo-sporins
26. Hypoprothrombinemia associated with cefperazone therapy
27. Diarrhoea associated with ceftriaxone and its implications in paediatric patients
28. Third generation cephalosporins: safety profiles after 10 years of clinical use
29. Cephalosporins — cefotaxime 10 years later, a major drug with continued use
30. Ceftriaxone-associated pseudolithiasis in adults
31. Bleeding disorders associated with new cephalosporins
32. Ceftriaxone-induced granulocytopenia related to a particular mechanism of granulocy-topoiesis inhibition
33. Effects of cephalosporins on bil-irubin-albumin binding
34. ‘Immune complex’ mediated intravascular haemolysis due to IgM cephalosporin-dependent antibody
35. Cefoperazone for empiric therapy in patients with impaired renal function
36. Potential for bleeding with the new β-lactam antibiotics
37. Reversible ceftriaxone-associated biliary pseudolithiasis in children
38. Cefotaxime-induced immune haemolytic anemia due to antibodies reacting in vitro by more than one mechanism
39. Considerations regarding clinical safety and tolerability of antibiotics in serious and nosocomial infections
40. Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections: randomized, double blind trial
41. Ceftriaxone compared with cefotaxime for serious bacterial infections
42. Comparison of ceftriaxone with standard therapy for bacterial meningitis
43. Antimicrobial therapy for paediatric patients
44. Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media
45. Randomized comparative study of cefoxime versus cephalexin in acute bacterial exacerbations of chronic bronchitis
46. Cefaclor-associated serum sickness-like disease: eight cases and review of the literature
47. Prolonged bleeding times and bleeding diathesis associated with moxalactam administration
48. Safety profile of cefprozil
49. A multicenter trial comparing efficacy and safety of cefuroxime axetil and cefaclor in pneumonia of adults